Journal of Oncology
Volume 2010 (2010), Article ID 149362, 11 pages
doi:10.1155/2010/149362
Review Article

A Current Review of Targeted Therapeutics for Ovarian Cancer

Susana M. Campos1 and Sue Ghosh2

1Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
2Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

Received 9 July 2009; Accepted 28 September 2009

Academic Editor: Maurie M. Markman

Copyright © 2010 Susana M. Campos and Sue Ghosh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Bookman, K. M. Darcy, D. Clarke-Pearson, R. A. Boothby, and I. R. Horowitz, “Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group,” Journal of Clinical Oncology, vol. 21, no. 2, pp. 283–290, 2003. View at Publisher · View at Google Scholar
  2. M. S Gordon, D. Matei, C. Aghajanian, et al., “Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status,” Journal of Clinical Oncology, vol. 23, no. 16S, 2005, abstract 5051.
  3. M. V. Seiden, H. A. Burris, U. Matulonis, et al., “A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies,” Gynecologic Oncology, vol. 104, no. 3, pp. 727–731, 2007. View at Publisher · View at Google Scholar · View at PubMed
  4. E. M. Posadas, M. S. Liel, V. Kwitkowski, et al., “A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer,” Cancer, vol. 109, no. 7, pp. 1323–1330, 2007. View at Publisher · View at Google Scholar · View at PubMed
  5. A. N. Gordon, N. Finkler, R. P. Edwards, et al., “Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study,” International Journal of Gynecological Cancer, vol. 15, no. 5, pp. 785–792, 2005. View at Publisher · View at Google Scholar · View at PubMed
  6. S. Campos, O. Hamid, M. V. Seiden, et al., “Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5597–5604, 2005. View at Publisher · View at Google Scholar · View at PubMed
  7. R. A. Burger, M. W. Sill, B. J. Monk, B. E. Greer, and J. I. Sorosky, “Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5165–5171, 2007. View at Publisher · View at Google Scholar · View at PubMed
  8. S. A. Cannistra, U. A. Matulonis, R. T. Penson, et al., “Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5180–5186, 2007. View at Publisher · View at Google Scholar · View at PubMed
  9. A. A. Garcia, H. Hirte, G. Fleming, et al., “Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia,” Journal of Clinical Oncology, vol. 26, no. 1, pp. 76–82, 2008. View at Publisher · View at Google Scholar · View at PubMed
  10. J. D. Wright, A. Hagemann, J. S. Rader, et al., “Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma,” Cancer, vol. 107, no. 1, pp. 83–89, 2006. View at Publisher · View at Google Scholar · View at PubMed
  11. J. C. Chura, K. Van Iseghem, L. S. Downs Jr., L. F. Carson, and P. L. Judson, “Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer,” Gynecologic Oncology, vol. 107, no. 2, pp. 326–330, 2007. View at Publisher · View at Google Scholar · View at PubMed
  12. H. S. Nimeiri, A. M. Oza, R. J. Morgan, et al., “Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia,” Gynecologic Oncology, vol. 110, no. 1, pp. 49–55, 2008. View at Publisher · View at Google Scholar · View at PubMed
  13. B. J. Monk, E. Han, C. A. Josephs-Cowan, G. Pugmire, and R. A. Burger, “Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer,” Gynecologic Oncology, vol. 102, no. 2, pp. 140–144, 2006. View at Publisher · View at Google Scholar · View at PubMed
  14. F. Simpkins, J. L. Belinson, P. G. Rose, et al., “Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening,” Gynecologic Oncology, vol. 107, no. 1, pp. 118–123, 2007. View at Publisher · View at Google Scholar · View at PubMed
  15. K. F. McGonigle, H. G. Muntz, J. L. Vuky, et al., “A phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5551.
  16. J. P. Micha, B. H. Goldstein, M. A. Rettenmaier, et al., “A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer,” International Journal of Gynecological Cancer, vol. 17, no. 4, pp. 771–776, 2007. View at Publisher · View at Google Scholar · View at PubMed
  17. N. S. Azad, E. M. Posadas, V. E. Kwitkowski, et al., “Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity,” Journal of Clinical Oncology, vol. 26, no. 22, pp. 3709–3714, 2008. View at Publisher · View at Google Scholar · View at PubMed
  18. R. T. Penson, S. Cannistra, M. V. Seiden, et al., “Phase II study of carboplatin, paclitaxel and bevacizumab as first line therapy and consolidation for advanced mullerian tumors,” Journal of Clinical Oncology, vol. 24, no. 18S, 2006, abstract 5020.
  19. S. C. Campos, D. S. Dizon, S. A. Cannistra, et al., “Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian mullerian cancers,” Journal of Clinical Oncology, vol. 25, no. 18S, 2007, abstract 5517.
  20. S. M. Campos, R. T. Penson, U. Matulonis, et al., “STAC: a randomized phase II trial of avastin or avastin + erlotinib as first line consolidation chemotherapy after standard therapy,” British Gynecological Society Meeting, 2008, abstract 93.
  21. U. A. Matulonis, S. Berlin, P. Ivy, et al., “Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube and peritoneal cancer,” Journal of Clinical Oncology, vol. 27, no. 33, pp. 5601–5606, 2009. View at Publisher · View at Google Scholar · View at PubMed
  22. H. W. Hirte, L. Vidal, G. F. Fleming, et al., “A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer. Final results of a PMH, Chicago and California consortia trial,” Journal of Clinical Oncology, vol. 26, no. 298S, 2008, abstract 5521.
  23. R. Buckstein, R. M. Meyer, L. Seymour, et al., “Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND. 182–185,” Current Oncology, vol. 14, no. 4, pp. 154–161, 2007. View at Publisher · View at Google Scholar
  24. M. Friedlander, K. C. Hancock, B. Benigno, et al., “Pazopanib (GW 786034) is active in women with advanced epithelial ovarian, fallopian tube, and peritoneal cancers: results of a phase II study,” Journal of Clinical Oncology, vol. 25, no. 18S, 2007, abstract 5561.
  25. J. J. Biagi, A. M. Oza, R. Grimshaw, et al., “A phase II study of sunitinib (SU11248) in patients with recurrent epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma-NCIC CTG IND 185,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5522.
  26. D. Matei, M. W. Still, K. DeGeest, et al., “Phase II study of sorafenib in persistent or recurrent epithelial ovarian cancer( EOC) or primary peritoneal cancer ( PPC): a Gynecology Oncology Group (GOG) study,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5537.
  27. E. J. Battegay, “Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects,” Journal of Molecular Medicine, vol. 73, no. 7, pp. 333–346, 1995.
  28. J. Folkman, “Angiogenesis in cancer, vascular, rheumatoid and other disease,” Nature Medicine, vol. 1, no. 1, pp. 27–31, 1995.
  29. H. C. Hollingsworth, E. C. Kohn, S. M. Steinberg, M. L. Rothenberg, and M. J. Merino, “Tumor angiogenesis in advanced stage ovarian carcinoma,” The American Journal of Pathology, vol. 147, no. 1, pp. 33–41, 1995.
  30. H. F. Dvorak, “Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy,” Journal of Clinical Oncology, vol. 20, no. 21, pp. 4368–4380, 2002. View at Publisher · View at Google Scholar
  31. J. Folkman, “Tumor angiogenesis: therapeutic implications,” The New England Journal of Medicine, vol. 285, no. 21, pp. 1182–1186, 1971.
  32. N. Ferrara, “Role of vascular epidermal growth factor in regulation of angiogenesis,” Kidney International, vol. 56, no. 3, pp. 794–814, 1995. View at Publisher · View at Google Scholar · View at PubMed
  33. A. A. Alvarez, H. R. Krigman, R. S. Whitaker, R. K. Dodge, and G. C. Rodriguez, “The prognostic significance of angiogenesis in epithelial ovarian carcinoma,” Clinical Cancer Research, vol. 5, no. 3, pp. 587–591, 1999.
  34. G. Gasparini, E. Bonoldi, G. Viale, et al., “Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas,” International Journal of Cancer, vol. 69, no. 3, pp. 205–211, 1996. View at Publisher · View at Google Scholar
  35. G. H. Shen, M. Ghazizadeh, O. Kawanami, et al., “Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma,” British Journal of Cancer, vol. 83, no. 2, pp. 196–203, 2000. View at Publisher · View at Google Scholar · View at PubMed
  36. M. Sönmezer, M. Güngör, A. Ensari, and F. Ortaç, “Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor β and vascular endothelial growth factor,” International Journal of Gynecological Cancer, vol. 14, no. 1, pp. 82–88, 2004. View at Publisher · View at Google Scholar
  37. P. J. Paley, K. A. Staskus, K. Gebhard, et al., “Vascular endothelial growth factor expression in early stage ovarian carcinoma,” Cancer, vol. 80, no. 1, pp. 98–106, 1997. View at Publisher · View at Google Scholar
  38. E. M. Hartenbach, T. A. Olson, J. J. Goswitz, et al., “Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas,” Cancer Letters, vol. 121, no. 2, pp. 169–175, 1997.
  39. N. Colombo, G. Mangili, S. Mammoliti, et al., “Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: preliminary results of a pilot study,” Journal of Clinical Oncology, vol. 26, 2008, abstract 14598.
  40. W. Tew, N. Colombo, I. Ray-Caquard, et al., “VEGF-Trap for patients with recurrent platinum resistant epithelial ovarian cancer,” Journal of Clinical Oncology, vol. 25, no. 18S, 2008, abstract 5508.
  41. D. S. Alberts, P. Y. Liu, E. V. Hannigan, et al., “Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer,” The New England Journal of Medicine, vol. 335, no. 26, pp. 1950–1955, 1996. View at Publisher · View at Google Scholar
  42. M. Markman, B. N. Bundy, D. S. Alberts, et al., “Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group,” Journal of Clinical Oncology, vol. 19, no. 4, pp. 1001–1007, 2001.
  43. D. K. Armstrong, B. Bundy, L. Wenzel, et al., “Intraperitoneal cisplatin and paclitaxel in ovarian cancer,” The New England Journal of Medicine, vol. 354, no. 1, pp. 34–43, 2006. View at Publisher · View at Google Scholar · View at PubMed
  44. J. A. Konner, D. Grabon, S. Pezzulli, et al., “A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer,” Journal of Clinical Oncology, vol. 27, no. 15S, 2009, abstract 5539.
  45. D. D. McMeekin, G. Lanneau, J. Curiel, et al., “Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers,” Journal of Clinical Oncology, vol. 27, no. 15S, 2009, abstract 5540.
  46. E. Pujade-Lauraine, S. Mahner, J. Kaern, et al., “A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG),” Journal of Clinical Oncology, vol. 27, no. 18S, 2009, abstract LBA5509.
  47. J. Mendelsohn and J. Baselga, “The EGF receptor family as targets for cancer therapy,” Oncogene, vol. 19, no. 56, pp. 6550–6565, 2000. View at Publisher · View at Google Scholar · View at PubMed
  48. B. F. El-Rayes and P. M. LoRusso, “Targeting the epidermal growth factor receptor,” British Journal of Cancer, vol. 91, no. 3, pp. 418–424, 2004. View at Publisher · View at Google Scholar · View at PubMed
  49. R. Nahta and F. J. Esteva, “HER-2-targeted therapy: lessons learned and future directions,” Clinical Cancer Research, vol. 9, no. 14, pp. 5078–5084, 2003.
  50. M. A. Bookman, “Biological therapy of ovarian cancer: current directions,” Seminars in Oncology, vol. 25, no. 3, pp. 381–396, 1998.
  51. S. B. Kaye, C. J. Poole, M. Bidzinksi, et al., “A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin based chemotherapy in patients with relapsed platinum sensitive ovarian cancer,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5520.
  52. L. Amler, S. Makhija, and T. Januario, “Her 2 pathway gene expression analysis in a phase II study of pertuzumab+ gemcitabine vs. gemcitabine + placebo in patients with platinum resistant epithelial ovarian cancer,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5562.
  53. S. Makhija, D. Glenn, F. Ueland, et al., “Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer,” Journal of Clinical Oncology, vol. 25, no. 18S, 2007, abstract 5507.
  54. M. S. Gordon, D. Matei, C. Aghajanian, et al., “Clinical activity of pertuzumab (rhuMAb2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predicative relationship between tumor HER 2 activation status,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4324–4332, 2006.
  55. R. J. Schilder, M. V. Sill, W. Chen, et al., “Phase II study of Getinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecological Oncology Group Study,” Clinical Cancer Research, vol. 11, no. 15, pp. 5539–5548, 2005. View at Publisher · View at Google Scholar · View at PubMed
  56. B. Tanner, D. Hasenclever, K. Stern, et al., “ErbB-3 predicts survival in ovarian cancer,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4317–4323, 2006. View at Publisher · View at Google Scholar · View at PubMed
  57. R. S. Herbst, D. H. Johnson, E. Mininberg, et al., “Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 11, pp. 2544–2555, 2005.
  58. J. Andrae, R. Gallini, and C. Betsholtz, “Role of platelet-derived growth factors in physiology and medicine,” Genes & Development, vol. 22, no. 10, pp. 1276–1312, 2008. View at Publisher · View at Google Scholar · View at PubMed
  59. J. Schmitt and D. Matei, “Platelet-derived growth factor pathway inhibitors in ovarian cancer,” Clinical Ovarian Cancer, vol. 1, no. 2, pp. 120–126, 2008.
  60. X. Mao and R. A. Hamoudi, “Molecular and cytogenetic analysis of glioblastoma multiforme,” Cancer Genetics and Cytogenetics, vol. 122, no. 2, pp. 87–92, 2000. View at Publisher · View at Google Scholar
  61. M. Carroll, M. H. Tomasson, G. F. Barker, T. R. Golub, and D. G. Gilliland, “The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 25, pp. 14845–14850, 1996.
  62. M. C. Heinrich, C. L. Corless, A. Duensing, et al., “PDGFRA activating mutations in gastrointestinal stromal tumors,” Science, vol. 299, no. 5607, pp. 708–710, 2003. View at Publisher · View at Google Scholar · View at PubMed
  63. S. M. Apte, C. D. Bucana, J. J. Killion, D. M. Gershenson, and I. J. Fidler, “Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines,” Gynecologic Oncology, vol. 93, no. 1, pp. 78–86, 2004. View at Publisher · View at Google Scholar · View at PubMed
  64. R. L. Coleman, R. R. Broaddus, D. C. Bodurka, et al., “Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers,” Gynecologic Oncology, vol. 101, no. 1, pp. 126–131, 2006. View at Publisher · View at Google Scholar · View at PubMed
  65. E. M. Posadas, V. Kwitkowski, H. L. Kotz, et al., “A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling,” Cancer, vol. 110, no. 2, pp. 309–317, 2007. View at Publisher · View at Google Scholar · View at PubMed
  66. D. Matei, D. D. Chang, and M.-H. Jeng, “Imatinib mesylate (Gleevac) inhibits ovarian cancer cell growth through a mechanisms dependent on platelet derived growth factor α and Akt inactivation,” Clinical Cancer Research, vol. 10, no. 2, pp. 681–690, 2004. View at Publisher · View at Google Scholar
  67. E. Buchdunger, J. Zimmermann, H. Mett, et al., “Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylamniopyridmidine class,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 7, pp. 2558–2562, 1995.
  68. H. Youssoufian, R. J. Amato, C. J. Sweeney, et al., “Phase I study of IMC-3G3, and IgG1 monoclonal antibody targeting PDGFRα in patients with advanced solid malignancies,” Journal of Clinical Oncology, vol. 26, no. 636S, 2008.
  69. G. C. Jayson, G. J. M. Parker, S. Mullamitha, et al., “Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume,” Journal of Clinical Oncology, vol. 23, no. 5, pp. 973–981, 2005. View at Publisher · View at Google Scholar · View at PubMed
  70. R. J. Schilder, M. W. Sill, R. B. Lee, et al., “Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 26, no. 20, pp. 3418–3425, 2008. View at Publisher · View at Google Scholar · View at PubMed
  71. D. S. Alberts, P. Y. Liu, S. P. Wilczynski, et al., “Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer,” International Journal of Gynecological Cancer, vol. 17, no. 4, pp. 784–788, 2007. View at Publisher · View at Google Scholar · View at PubMed
  72. F. Hilberg, G. J. Roth, M. Krssak, et al., “BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy,” Cancer Research, vol. 68, no. 12, pp. 4774–4782, 2008. View at Publisher · View at Google Scholar · View at PubMed
  73. J. A. Ledermann, G. J. Rustin, A. Hackshaw, et al., “A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC),” Journal of Clinical Oncology, vol. 27, no. 15S, 2009, abstract 5501.
  74. S. Markert, S. Lassmann, B. Gabriel, et al., “Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue,” Anticancer Research, vol. 28, no. 6, pp. 3567–3572, 2008.
  75. H. Elnakat and M. Ratnam, “Role of folate receptor genes in reproduction and related cancers,” Frontiers in Bioscience, vol. 11, pp. 506–519, 2006. View at Publisher · View at Google Scholar
  76. K. R. Kalli, A. L. Oberg, G. L. Keeney, et al., “Folate receptor alpha as a tumor target in epithelial ovarian cancer,” Gynecologic Oncology, vol. 108, pp. 619–626, 2008. View at Publisher · View at Google Scholar · View at PubMed
  77. K. L. Knutson, C. J. Krco, C. L. Erskine, et al., “T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4254–4261, 2006. View at Publisher · View at Google Scholar · View at PubMed
  78. J. J. Hernando, T.-W. Park, H.-P. Fischer, et al., “Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-α for relapsed metastatic ovarian cancer,” The Lancet Oncology, vol. 8, no. 5, pp. 451–454, 2007. View at Publisher · View at Google Scholar · View at PubMed
  79. W. Ebel, E. L. Routhier, B. Foley, et al., “Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha,” Cancer Immunity, vol. 7, pp. 6–13, 2007.
  80. D. K. Armstrong, A. Bicher, R. L. Coleman, et al., “Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5500.
  81. D. Ford, D. F. Easton, D. T. Bishop, S. A. Narod, and D. E. Goldgar, “Risks of cancer in BRCA1-mutation carriers,” The Lancet, vol. 343, no. 8899, pp. 692–695, 1994. View at Publisher · View at Google Scholar
  82. C. J. Lord and A. Ashworth, “Targeted therapy for cancer using PARP inhibitors,” Current Opinion in Pharmacology, vol. 8, no. 4, pp. 363–369, 2008. View at Publisher · View at Google Scholar · View at PubMed
  83. A. N. J. Tutt, C. J. Lord, N. McCabe, et al., “Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 70, pp. 139–148, 2005. View at Publisher · View at Google Scholar · View at PubMed
  84. P. C. Fong, D. S. Boss, C. P. Carden, et al., “AZD2281 [KU-0059436], a PARP [poly ADP-ribose polymerase] inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study,” Journal of Clinical Oncology, vol. 26, 2008, abstract 5510.
  85. C. Carden, et al., “Phase I study of AZD2281 [KU-0059436], a PARP [poly ADP-ribose polymerase] inhibitor: results in patients with BRCA deficient ovarian cancer,” in Proceedings of the National Cancer Research Institute Cancer Conference, vol. 320, 2008, abstract BOA22.
  86. M. W. Audeh, R. T. Penson, M. Friedlander, et al., “Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer,” Journal of Clinical Oncology, vol. 27, no. 15S, 2009, abstract 5500.
  87. J. Z. Press, A. De Luca, N. Boyd, et al., “Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities,” BMC Cancer, vol. 8, article 17, 2008. View at Publisher · View at Google Scholar · View at PubMed
  88. E. A. Harrington, D. Bebbington, J. Moore, et al., “VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo,” Nature Medicine, vol. 10, no. 3, pp. 262–267, 2004. View at Publisher · View at Google Scholar · View at PubMed
  89. N. Keen and S. Taylor, “Aurora-kinase inhibitors as anticancer agents,” Nature Reviews Cancer, vol. 4, no. 12, pp. 927–936, 2004. View at Publisher · View at Google Scholar · View at PubMed
  90. N. Matthews, C. Visintin, B. Hartzoulakis, A. Jarvis, and D. L. Selwood, “Aurora A and B kinases as targets for cancer: will they be selective for tumors?” Expert Review of Anticancer Therapy, vol. 6, no. 1, pp. 109–120, 2006. View at Publisher · View at Google Scholar · View at PubMed
  91. H. Zhou, J. Kuang, L. Zhong, et al., “Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation,” Nature Genetics, vol. 20, no. 2, pp. 189–193, 1998. View at Publisher · View at Google Scholar · View at PubMed
  92. H. Katayama, K. Sasai, H. Kawai, et al., “Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53,” Nature Genetics, vol. 36, no. 1, pp. 55–62, 2004. View at Publisher · View at Google Scholar · View at PubMed
  93. C. N. Landen Jr., Y. G. Lin, A. Immaneni, et al., “Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients,” Clinical Cancer Research, vol. 13, no. 14, pp. 4098–4104, 2007. View at Publisher · View at Google Scholar · View at PubMed
  94. M. M. Tanner, S. Grenman, A. Koul, et al., “Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer,” Clinical Cancer Research, vol. 6, no. 5, pp. 1833–1839, 2000.
  95. A. A. Kulkarni, M. Loddo, E. Leo, et al., “DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma,” Clinical Cancer Research, vol. 13, no. 20, pp. 6153–6161, 2007. View at Publisher · View at Google Scholar · View at PubMed
  96. Y. G. Lin, A. Immaneni, W. M. Merritt, et al., “Targeting Aurora kinase with MK-0457 inhibits ovarian cancer growth,” Clinical Cancer Research, vol. 14, no. 17, pp. 5437–5446, 2008. View at Publisher · View at Google Scholar · View at PubMed
  97. C. D. Scharer, N. Laycock, A. O. Osunkoya, et al., “Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells,” Journal of Translational Medicine, vol. 6, article 79, 2008. View at Publisher · View at Google Scholar · View at PubMed
  98. M. G. Manfredi, J. A. Ecsedy, K. A. Meetze, et al., “Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora a kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 10, pp. 4106–4111, 2007. View at Publisher · View at Google Scholar · View at PubMed
  99. R. Bhattacharya, J. Kwon, B. Ali, et al., “Role of hedgehog signaling in ovarian cancer,” Clinical Cancer Research, vol. 14, no. 23, pp. 7659–7666, 2008. View at Publisher · View at Google Scholar · View at PubMed
  100. X. Chen, A. Horiuchi, N. Kikuchi, et al., “Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis,” Cancer Science, vol. 98, no. 1, pp. 68–76, 2007. View at Publisher · View at Google Scholar · View at PubMed
  101. B. H. Jiang and L. Z. Liu, “PI3K/PTEN signaling in tumorgenesis and angiogenesis,” Biochimica et Biophysica Acta, vol. 1784, no. 1, pp. 150–158, 2008.
  102. I. Sansal and W. R. Sellers, “The biology and clinical relevance of the PTEN tumor suppressor pathway,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2954–2963, 2004. View at Publisher · View at Google Scholar · View at PubMed
  103. J .F. Gera, I. K. Mellinghoff, Y. Shi, et al., “AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D and c-myc expression,” The Journal of Biological Chemistry, vol. 279, no. 4, pp. 2737–2746, 2004.
  104. S. Mabuchi, D. A. Altomare, M. Cheung, et al., “RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model,” Clinical Cancer Research, vol. 13, no. 14, pp. 4261–4270, 2007. View at Publisher · View at Google Scholar · View at PubMed